Expanded access for ritlecitinib in severe hair loss
Treatments studied
Part of Skin clinical trials.
This trial provides early access to an investigational drug called ritlecitinib for people with severe alopecia areata who have not responded to other treatments. It aims to help regrow hair by targeting the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lost at least half of the hair on your scalp due to alopecia areata.
- You have tried all standard treatments for alopecia areata available in your country, but they did not work or caused side effects.
- You are willing to undergo additional screening to confirm eligibility.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if the medicine ritlecitinib can help regrow hair in people with alopecia areata, a condition that causes patchy hair loss. It's for young people and adults who have lost between 20% and 50% of their scalp hair for at least 6 months but no more than 10 years.
This study tests two different doses of a pill called ritlecitinib to see if it can help regrow hair in people with significant hair loss from alopecia areata. It is for people aged 12 and older who have lost at least half of their scalp hair.
This Phase 2 study tests ruxolitinib to see if it safely helps regrow hair in people whose alopecia areata is linked to APECED (a rare immune condition). You may qualify if you have significant scalp hair loss for at least 6 months and haven’t had regrowth with other treatments.
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
This study tests a pill called baricitinib (a JAK inhibitor) to see if it can stop rapid hair loss and help hair regrow in people with recent, active alopecia areata. It focuses on those who have been shedding hair for less than three months, so it might stop the process earlier than usual.
This study tests an investigational drug to see if it can help people with severe alopecia areata, a condition that causes hair loss. It may help regrow hair.
Hear when a new Alopecia Areata trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.